Copyright
©The Author(s) 2022.
World J Diabetes. Apr 15, 2022; 13(4): 282-307
Published online Apr 15, 2022. doi: 10.4239/wjd.v13.i4.282
Published online Apr 15, 2022. doi: 10.4239/wjd.v13.i4.282
Figure 1 Different lines for management of insulin resistance.
DPP4: Dipeptidyl peptidase-4 inhibitors; GLP-1: Glucagon-like peptide-1; PPAR: Peroxisome proliferator-activated receptor; SNDRI: Serotonin-norepinephrine-dopamine reuptake inhibitor.
- Citation: Al-Beltagi M, Bediwy AS, Saeed NK. Insulin-resistance in paediatric age: Its magnitude and implications. World J Diabetes 2022; 13(4): 282-307
- URL: https://www.wjgnet.com/1948-9358/full/v13/i4/282.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i4.282